GlassScriptPhysician profile
Mildred A Mcafee
NPI 1417994823
$4,704.26
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,099 · 2020: $497 · 2021: $302 · 2022: $158 · 2023: $373 · 2024: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $705.13 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $575.98 | 2019-2020 | |
| Amgen INC. | $372.77 | 2019-2020 | |
| Pfizer INC. | $301.96 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $295.08 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $287.83 | 2019 | |
| Sage Therapeutics, LLC | $210.77 | 2022-2023 | |
| Allergan, INC. | $203.27 | 2019-2020 | |
| Lilly USA, LLC | $170.94 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.88 | 2019-2021 | |
| Novo Nordisk INC | $159.44 | 2019-2024 | Wegovy, Ozempic |
| Amarin Pharma, INC. | $158.98 | 2019-2020 | |
| Alphatec Spine, INC | $141.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $140.96 | 2019 | |
| Glaxosmithkline, LLC. | $132.79 | 2024 | Arexvy, Shingrix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $122.48 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $107.12 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.00 | 2020 | |
| Genentech, INC. | $85.71 | 2023 | |
| Abbvie INC. | $55.80 | 2021-2022 | |
| Corcept Therapeutics | $45.14 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $32.74 | 2019 | |
| Zealand Pharma US, INC. | $29.02 | 2021 | |
| Merck Sharp & Dohme LLC | $22.35 | 2019 | |
| Insulet Corporation | $17.07 | 2021 | |
| Shire North American Group INC | $16.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.56 | 2020 | |
| Tandem Diabetes Care, INC. | $14.14 | 2019 | |
| Genentech USA, INC. | $12.12 | 2019 | |
| Horizon Therapeutics Plc | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mildred Mcafee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.